Drugs in the Pipeline
FDA Grants Xalkori Priority Review for Non-Small Cell Lung Cancer
The FDA has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for Xalkori (crizotinib; Pfizer).
Your search for non small cell lung cancer returned 92 results
Drugs in the Pipeline
Study: Longer Overall Survival for Keytruda vs. Docetaxel
Merck announced that the KEYNOTE-010 study of Keytruda (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) met its primary endpoint.
Drugs in the Pipeline
PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Positive Outcomes Observed with Xalkori in NSCLC Study
Pfizer announced results from PROFILE 1014, a Phase 3 study of Xalkori (crizotinib) in previously untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
AbbVie Launches Veliparib Trial for NSCLC
AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Phase 2 Trial Update of Ramucirumab for NSCLC
Lilly announced new data from two Phase 2 ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Phase 3 Trial Update of Afatinib for Advanced non-Small Cell Lung Cancer
Boehringer Ingelheim announced results from its LUX-Lung 3 Phase 3 clinical trial of afatinib in patients with advanced non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline
Phase 3 Trial Update of Sorafenib for Advanced Non Small-cell Lung Cancer
Sorafenib does not improve OS for patients with advanced NSCLC, but it may benefit a subset of patients whose tumors harbor EGFR mutations.
Drugs in the Pipeline
Retaspimycin HCl Falls Short in NSCLC Trial
Phase 2 results announced for retaspimycin HCl (Infinity Pharmaceuticals) in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) who had a history of smoking.
